Home Newsletters Cell Therapy News US Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (Nivolumab...

US Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag^™ (Nivolumab and Relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

Justin.choi

March 21, 2022

Bristol Myers Squibb announced that OpdualagTM was approved by the FDA for the treatment of adult and pediatric patients 12 years of age or older with unresectable or metastatic melanoma.

[Bristol Myers Squibb]

Press Release